// App-Quantinova.ai

150 : Use of TMB and PD-L1 to predict outcomes of checkpoint inhibitor treatment.

Researchers

Presenter

  • Paul B. Robbins

Principal Investigators

  • Tina Krieger

  • Isobel Pearson

  • Judith Bell

  • Jim P. Doherty

Medical Centers

  • Pfizer Inc, New York, NY

  • RTI Health Solutions, Manchester, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • PharmAbcine Inc.

  • RTI Health Solutions

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

  • Tumor mutational burden

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved